Heparan sulfate (HS) appeared early in metazoan evolution. As such, many of the structural motifs (variably sulfated disaccharide subunits) that characterize HS (and heparin) were established early on and have been preserved in modern organisms. Thus, many of the biological functions associated with HS either occurred early in evolution or have depended on the subsequent evolution of the protein ligands that bind to the polysaccharide. Today, we know of literally hundreds of heparin-binding proteins, and many interactions have profound consequences in vertebrate and invertebrate physiology. This Perspective aims to provide an overview of HS structure, function, and biosynthesis and to set the stage for discussing the relationship between structure and function of these fascinating molecules and how altered HS biosynthesis and catabolism can lead to human disorders. HS proteoglycans Virtually all cells, from simple invertebrates to humans, have the capacity to produce HS. These polysaccharides represent a type of glycosaminoglycan characterized by alternating uronic acid (D-glucuronic acid [GlcA] or L-iduronic acid [IdoA]) and Dglucosamine (GlcN) units (Figure 1) (1). The chains rarely occur as free entities but rather form covalent complexes with specific "core" proteins. The composite glycoproteins constitute the superfamily of HS proteoglycans. Two major subfamilies of plasma membrane-bound core proteins can be distinguished by primary amino acid sequence homologies, the syndecans and glypicans (2). The four syndecans (designated […] Perspective Find the latest version:
PERSPECTIVE SERIES

Renato V. Iozzo, Series Editor
Heparan sulfate proteoglycans
Heparan sulfate (HS) appeared early in metazoan evolution. As such, many of the structural motifs (variably sulfated disaccharide subunits) that characterize HS (and heparin) were established early on and have been preserved in modern organisms. Thus, many of the biological functions associated with HS either occurred early in evolution or have depended on the subsequent evolution of the protein ligands that bind to the polysaccharide. Today, we know of literally hundreds of heparin-binding proteins, and many interactions have profound consequences in vertebrate and invertebrate physiology. This Perspective aims to provide an overview of HS structure, function, and biosynthesis and to set the stage for discussing the relationship between structure and function of these fascinating molecules and how altered HS biosynthesis and catabolism can lead to human disorders.
HS proteoglycans
Virtually all cells, from simple invertebrates to humans, have the capacity to produce HS. These polysaccharides represent a type of glycosaminoglycan characterized by alternating uronic acid (D-glucuronic acid [GlcA] or Liduronic acid [IdoA] ) and D-glucosamine (GlcN) units ( Figure 1 ) (1) . The chains rarely occur as free entities but rather form covalent complexes with specific "core" proteins. The composite glycoproteins constitute the superfamily of HS proteoglycans. Two major subfamilies of plasma membrane-bound core proteins can be distinguished by primary amino acid sequence homologies, the syndecans and glypicans (2) . The four syndecans (designated syndecan-1, -2, -3, and -4) have protein cores with characteristic structural domains (3). The variable ectodomain, exposed to the extracellular milieu, contains 3-5 HS chains in conserved motifs, although hybrid forms containing both HS and another glycosaminoglycan (chondroitin sulfate) are expressed in some tissues. A short hydrophobic transmembrane segment tethers the proteoglycan to the plasma membrane. A protease cleavage site exists proximal to the ectodomain, and proteolysis results in shedding of the ectodomains from the cell surface. Membrane-bound syndecans can also be internalized by endocytosis and degraded in lysosomes, suggesting that the membrane domain or the cytoplasmic tails contain sequences that can interact with proteins involved in endocytosis (4) . The cytoplasmic domain also contains peptide sequences that bind to cytoskeletal proteins and that serve as substrates for cellular kinases. Thus, the syndecans can act as signaling molecules (5, 6) .
The glypicans (six members) are distinguished by their cysteine-rich globular ectodomains, and the presence of 2-3 HS chains attached just between the globular domain and the glycosylphosphatidylinositol moiety that anchors it to the outer leaflet of the plasma membrane (7) . No release of glypicans by a phospholipase C-type mechanism has been documented as yet, but like syndecans, the glypicans can be degraded by endocytosis and lysosomal degradation (8) .
Several minor membrane proteoglycans containing HS chains have been described as well (epican, betaglycan, and others) (1) . In addition, cells that produce basement membranes secrete the HS proteoglycans, perlecan, agrin, and collagen XVIII (9, 10) . The individual glypicans, syndecans, and basement membrane HS proteoglycans are expressed in a tissue-specific manner.
Lower organisms, such as Drosophila melanogaster and Caenorhabditis elegans, express homologs of glypican, syndecan, and perlecan (11) . In contrast to the multiple isoforms found in vertebrates, these organisms generally contain only one copy of syndecan and perlecan, and two copies of glypican are present in flies. Proteoglycans are also present in very ancient multicellular organisms such as Hydra, but the core proteins in these species have not yet been characterized (12) . Thus, throughout evolution the HS proteoglycans have played fundamental roles in development and physiology common to a multitude of living creatures.
Structural diversity of HS
The tissue-specific expression of individual proteoglycan core proteins will obviously determine when and where HS chains are expressed. However, ligand binding by proteoglycans depends on the structure of the HS chains. As shown in Figure 1 , HS can be analyzed in terms of disaccharide composition; the disaccharides are distinguished by the presence of variably sulfated or nonsulfated GlcA/IdoA and GlcN residues. Generally, the same set of disaccharides exists in most tissues, but their relative content varies quantitatively. For example, the disaccharide GlcA-GlcNS3S occurs predominantly in endothelial cells and connective tissue mast cells, as this unit is a critical substructure in the pentasaccharide sequence that binds antithrombin (13, 14) . In contrast, kidney HS contains a large amount of IdoA2S-GlcNS3S, but the precise function of this unit in ligand binding is not known (15) . Interestingly, the basic structural disaccharides of HS appear to be quite ancient.
Another way to characterize structure is in terms of the relative distribution of the major N-substituents of the GlcN residues: tracts of contiguous N-acetylated disaccharide units (NA domains), contiguous N-sulfated sequences of variable length (NS domains), and alternating N-acetylated and N-sulfated units (NA/NS domains) ( Figure 1 ). Such N-substitution patterns appear to be characteristic of the cells/tissues from which the HS was obtained. Notably, heparin, the mast cell polysaccharide, may be considered essentially a single, unusually extended NS domain. Since other modifications, such as O-sulfation and epimerization of GlcA to L-IdoA, depend on prior N-sulfation of GlcN units, the modified disaccharide units tend to cluster in the NS or NA/NS domains (16) .
The disaccharide composition and the arrangement of NA and NS domains do not by themselves define binding sites for specific ligands. Instead, binding occurs to specific sets of variably modified disaccharides usually within the NS or NA/NS domains (17, 18) . The beststudied example to date is the "lock-and-key" interaction between HS/heparin and antithrombin, which leads to inactivation of thrombin, factor Xa, and other serine proteinases of the coagulation cascade. This interaction depends on a very specific structure of a pentasaccharide that contains a central 3-O-sulfated GlcN residue (GlcNAc6SGlcAGlcNS3S6SIdoA2SGlcNS6S) (see . In other cases, the chain may act as a template, approximating a ligand with its binding partner (13, 22, 23) . The expression of binding sites occurs in a tissue-specific manner and can change during development, aging, and disease. An unexplored question concerns the potential variation of structure in a given tissue in different individuals of the same species that might arise from differences in nutrition or genetic background.
HS biosynthesis depends on many enzymes
The fine structure of the chains ultimately depends on the regulated expression and action of multiple glycosyltransferases, sulfotransferases, and an epimerase, which are arrayed in the lumen of the Golgi apparatus ( Figure  1 ). In addition, a series of cytoplasmic enzymes are needed to catalyze nucleotide sugar (UDP-Xyl, UDP-Gal, UDP-GlcA, UDP-GlcNAc) and nucleotide sulfate (PAPS) formation, and multiple membrane transporters to import the nucleotides from the cytosol to the lumen of Golgi apparatus (24, 25) . The assembly process may also depend on the availability of GlcN or other sugars in the diet. Synthesis initiates through the assembly of a linkage tetrasaccharide, GlcAβ1,3Galβ1,3Galβ1,4Xylβ1-, on serine residues in the proteoglycan core polypeptide (26) . This process is catalyzed by four enzymes that add individual sugar residues sequentially to the nonreducing end of the growing chain. The initiating reaction, catalyzed by xylosyltransferase, occurs at specific sites, defined by SerGly residues flanked by one or more acidic residues (27) . The linkage region also undergoes phosphorylation at C2 of xylose and sulfation at C4 or C6 of the galactose residues, but the functions of these modifications remain unclear (26) . These linkage region modifications tend to be substoichiometric and are absent in some proteoglycans. Phosphorylation may be transient, suggesting a role in secretion or in regulation of the assembly process.
After assembly of the linkage region, one or more α-GlcNAc transferases add a single α1,4-linked GlcNAc unit to the chain, which commits the intermediate to the assembly of HS. Competition exists between this reaction and the addition of a β1,4-linked GalNAc residue catalyzed by a separate enzyme. When the latter reaction occurs, the intermediate serves as a primer for chondroitin sulfate formation. Evidence suggests that amino acid determinants lying close to the glycosaminoglycan attachment site or structural domains at some distance away regulate this process, with chondroitin sulfate representing the default pathway (27) . Polymerization of HS then takes place by the alternating addition of GlcAβ1,4 and GlcNAcα1,4 residues, catalyzed by proteins now recognized as members of the exostosin family of tumor suppressors (see Duncan et al., this Perspective series, ref. 28). As the chain polymerizes, it undergoes a series of modifications that include GlcNAc N-deacetylation and N-sulfation, C5 epimerization of GlcA to IdoA, and variable O-sulfation at C2 of IdoA and GlcA, at C6 of GlcNAc and GlcNS units, and occasionally at C3 of GlcN residues (Figure 1) . The concerted action of the enzymes catalyzing these reactions results in the formation and organization of NA, NS, and NA/NS domains (16) .
Most of the enzymes involved in modifying the chain have now been purified and molecularly cloned. The GlcNAc N-deacetylase/N-sulfotransferase (NDST), the glucosaminyl 6-O-sulfotransferases (6OST), and the glucosaminyl 3-O-sulfotransferases (3OST) each represent a gene family whose members appear to be expressed in a tissue-specific and developmentally regulated pattern. Four NDSTs, five 3OSTs, and three 6OSTs are known. Substrate specificity studies performed in vitro indicate that the individual members of each enzyme subfamily catalyze the same reaction, but in different chemical contexts. For example, 3OST-1 is the only 3OST isozyme that can form the antithrombin binding sequence (i.e., domains containing GlcA-GlcNS3S). In contrast, 3OST-2 transfers sulfate to GlcA2S-GlcNS and IdoA2S-GlcNS, whereas 3OST-3A transfers sulfate to IdoA2S-GlcN, where the GlcN has an unsubstituted amino group, thus generating the binding site for the viral gD glycoprotein (29, 30) . The three 6-O-sulfotransferases add sulfate to the C6 of GlcN units, but the preferred location of the target relative to GlcA and IdoA varies (31) . The four NDST isozymes show variation in relative ratios of N-deacetylase and N-sulfotransferase activity. Modeling studies of the NDSTs against the crystal structure of the sulfotransferase domain of NDST1 (32) suggest that modulations of the binding cleft for the sugar chain may confer different substrate specificities for the enzymes (33) .
In contrast to these sulfotransferases, only one 2-Osulfotransferase (2OST) (34, 35) and one epimerase (36, 37) appear to exist in vertebrates. A survey of lower organisms has shown only single isozymes for the other sulfotransferases, suggesting that the ancestral forms of these enzymes perform all the basic reactions of HS biosynthesis required to generate the diversity of structure necessary for the various biological activities essential to the organisms.
In spite of the detailed information available about primary sequence of the isozymes and the evolving information about their substrate preferences, the formation of binding sites for antithrombin and glycoprotein gD remain the only known examples in which formation of a biologically significant structure can be correlated with expression of a specific isozyme (3OST-1 and 3OST-3A, respectively) (14, 30) . Notably, these examples both involve a "rare" component, i.e. the 3-O-sulfated GlcN residue, and are therefore, in a sense, conceptually simple compared with ligands that depend on the differential topology of major building blocks that are present in most HS species. Examples of such ligands include members of the FGF family, FGF1 and FGF2, with different binding requirements for GlcN 6-O-sulfate and IdoA 2-O-sulfate groups that are expressed in a selective fashion on distinct HS species (see Gallagher, this Perspective series, ref. 20 ). The precise structures of the corresponding binding sites and their distribution in HS chains are unknown. Clearly, a major effort in the field should aim at understanding the functional properties of the biosynthetic enzymes, as required to generate specific (or sometimes overlapping) binding sites in HS chains for a variety of protein ligands.
New insights into this problem should emerge from multiple directions. First, it should be possible to refine our understanding of the catalytic specificities of the various isozymes using recombinant enzymes with chemically defined substrates. Recent advances in carbohydrate synthesis (38, 39) represent a step in the right direction, but ultimately large scale synthesis of oligosaccharide libraries will be needed to elucidate substrate specificities in depth. Secondly, we need to understand the topographic organization of the biosynthetic apparatus, including the localization of enzymes in the Golgi membrane, their interaction with each other and with any auxiliary proteins, and their mode of processing the polysaccharide substrate. This objective can be approached in a variety of ways, ranging from immunochemical localization of native and mutated proteins in the cell (M.A.S. Pinhal and J.D. Esko, unpublished work) to the not yet realized assembly of model biosynthetic systems, using artificial membranes and recombinant proteins.
Insight from the derangement of HS function
Further insights into the relationship of enzyme structure and function should emerge from genetic studies in both invertebrates and vertebrates. Several groups simultaneously discovered that mutations in D. melanogaster affecting HS biosynthetic enzymes homologous to those found in mammals had deleterious effects on developmental patterning dependent on the wingless signaling pathway (see Filmus and Selleck, (41, 42) . Collectively, these studies provided the first evidence that glycosaminoglycan biosynthesis and the HS binding properties of various ligands are of physiological importance in vivo. However, due to the relative simplicity of the isozymes and core proteins expressed in flies and worms, these findings will not necessarily provide insight into the function of the multiple vertebrate homologs.
The development of homologous recombination techniques in murine ES cells provides a way to induce mutations in HS synthesis in mice (see Forsberg and Kjellén, this Perspective series, ref. 43) . A mutation in the gene for the IdoA 2-O-sulfotransferase by insertional mutagenesis causes renal agenesis and neonatal lethality in the mutant mice (44) . Analysis of tissues from these animals shows a complete loss of 2-O-sulfated IdoA containing disaccharides (J. Gallagher and C. Merry, unpublished work), consistent with the idea that only one 2OST exists. However, the surprising finding is that most tissues and organs develop normally, and many processes thought to depend on growth factor signaling occur apparently unhampered. Thus, signaling by way of FGFs does not obligatorily depend on the formation of HS sequences with the highest ligand affinity (45) .
Two of the NDST isozymes have been inactivated by homologous recombination. NDST1 mutants exhibit neonatal lethality due to defective lung development (46, 47) , whereas NDST2 defects have a restricted phenotype in which only heparin formation in connective tissue mast cells is affected (48, 49) . These findings indicate that one cannot predict whether a particular isozyme will be essential for embryogenesis. In those cases where the mutations result in lethality, conditional mutations are needed in which expression of genes can be ablated in a tissue-specific manner or in adult animals. New methods for making targeted mutations in mice have recently become available using the Cre-loxP recombination system. Several key steps in the biosynthetic pathway are now in the process of being targeted in this way in order to examine the effect of ablating specific isozymes on structure and function of HS in specific tissues (J.D.
Esko, unpublished results).
A priori, one can predict that mutations in every gene should be present in the human population. However, finding these individuals depends on whether the mutation led to death in utero or resulted in a clinical phenotype that an informed clinician would associate with altered HS formation. The defect in SimpsonGolabi-Behmel overgrowth syndrome has been traced to a chromosomal mutation in glypican-3 (see Filmus and Selleck, this Perspective series, ref. 40) . Moreover, hereditary multiple exostosis, a bone disorder characterized by cartilage-capped bony outgrowths from the growth plates, has been associated with alterations in the copolymerase required for HS biosynthesis (see Duncan et al., this series, ref. 28) . Although the actual molecular events underlying these diseases are unknown, one can already begin to glimpse the importance of HS in human growth and development. Harvesting the wealth of information that can be obtained from these unfortunate acts of heredity and from induced mutations in lower organisms remains an ongoing challenge.
